CM2 antigen, a potential novel molecule participating in glucuronide transport on rat hepatocyte canalicular membrane

L. Wang, J. Wang, X. Zhou, Y. Shi, S. Li, Z. Yang, D. Fan, Y. Han
1Division of Hepatology, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, Shaanxi Province, China
2Department of Pathology, The Fourth Military Medical University, Xi'an, Shaanxi Province, China

Abstract

The polarized molecules predominantly distributing at hepatocyte canalicular surface play a vital role in disclosing the process of bile formation and etiopathogenesis of cholestatic liver diseases. Therefore, it is important to find novel polarized molecules on hepatocyte canalicular membrane. In the present study, canalicular membrane vesicles (CMVs) isolated from rat hepatocyte by density gradient centrifugation were used as immunogens to produce hybridoma and 46 strains of monoclonal antibodies (mAb) against CMVs were obtained. With a series of morphological assay methods, including immunohistochemistry, immunofluorescence and immuno-electron microscope, the antigens recognized by canalicular mAb1 (CM1) and canalicular mAb2 (CM2) were confirmed to predominately distribute at hepatocyte canalicular membrane. Transport activity assay revealed that CM2 could inhibit ATP-dependent E217G uptake of rat hepatocyte CMVs. Meanwhile, Western blotting analysis showed that the molecular mass of CM2 antigen was approximately 110kDa, which was much less than Mr 180kDa of multidrug resistance-associated protein 2 (MRP2) involved in glucuronide transport. These data indicated that CM2 antigen might be a potential novel molecule participating in glucuronide transport on the hepatocyte canalicular membrane.

Introduction

Hepatocyte exhibits a striking polarity with three distinct membrane surfaces, which are sinusoidal, canalicular and lateral surfaces. Different surface represents the unique morphological and functional characteristics. Bile secretion is mediated by many polarized molecules on hepatocyte canalicular membrane, which is characterized by numerous microvilli and has special transport activities.1

So far, many polarized molecules including enzymes, receptors, transporters and exchangers, are identified to specifically localize to hepatocyte canalicular membrane.2 These polarized molecules play important roles in various liver diseases, especially in cholestatic liver diseases. Due to hepatocyte damage, liver plasma membrane fragments are released into the circulation and several canalicular membrane specific enzymes in serum, such as gamma-glutamyltransferase (γ-GT), alkaline phosphatase (ALP), leucine aminopeptidase (LAP) and 5'-nucleotidase (5'-Nu), have been deemed as clinical diagnostic markers.3,4 In addition, the absence or mutation of some transporters could directly lead to bile metabolism disorders. Dubin-Johnson syndrome, an autosomal recessive cholestatic disorder, results from the mutation of the multidrug resistance-associated protein 2 (MRP2) with the absence of MRP2 protein at hepatocyte canalicular membrane.5-7 Mutations in code of the familial intrahepatic cholestasis-1 (FIC1) contribute to Byler’s disease, progressive familial intrahepatic cholestasis (PFIC) type 1, with severe and progressive intrahepatic cholestasis.8,9 Besides, the lower expression, decreased immunoreactivities and defective transport activities of chloride-bicarbonate anion exchangers (AE2) could be associated with primary biliary cirrhosis (PBC) disease.8

Therefore, the present study aimed to find novel molecules distributing at the hepatocyte canalicular membrane with hybridoma technology and functional screening.

Materials and Methods

Isolation and identification of rat canalicular membrane vesicles

According to the method described previously,10-12 canalicular membrane vesicles (CMVs) and sinusoidal membrane vesicles (SMVs) were prepared from Sprague-Dawley rats liver homogenates using density gradient centrifugation method. Vesicles were suspended in 50 mM Tris/HCl (pH 7.4) buffer containing 250 mM sucrose and frozen in liquid nitrogen until further use. The morphological and biochemical characteristics of isolated CMVs and SMVs were confirmed by transmission electron microscopy and enzyme assay respectively as described in our published paper.12

Immunization of animals and production of hybridomas

The rat CMVs were used as immunogens to produce hybridoma. In each case, BALB/c mice were immunized with 100 μg proteins in 0.1ml Wanglee Freund’s adjuvant (Sigma, St. Louis, MO, USA) and boosted twice with 50 μg proteins in incomplete Freund’s adjuvant (Sigma) at 3-week intervals. After immunization, serological responses to CMVs were monitored by an enzyme linked immunosorbent assay (ELISA). Selected mice were intravenously boosted with 30 μg proteins in phosphate buffered saline (PBS) 3 days before sacrifice. According to the standard hybridoma technique, spleen cells were fused with SP2/0 myeloma cells using polyethylene glycol and hybridomas were cultured in HAT (hygromycin B, aminopterin and thymidine) selective medium. Seven-eight d after fusion, hybridoma cell supernatants were screened with ELISA and immunohistochemistry methods respectively. Positive hybridomas were cloned by limiting dilution.

ELISA

Ninety-six well ELISA plates (Corning...
sections were immersed in PBS containing 5% BSA and 5% NGS to block nonspecific immunoreactivity, incubated with CM1 or CM2 hybridoma cell supernatant and goat anti-mouse IgG conjugated to 1.4 nm gold particles at 1:100 dilution (NanoProbes, Stony Brook, NY, USA). After rinsing, sections were postfixed in 2% glutaraldehyde and silver enhancement was carried out in the dark with HQ Silver Kit (NanoProbes). After fixing with 0.5% osmium tetroxide in 0.1 M phosphate buffer for 1 h, immunolabeled sections were dehydrated in graded ethanol series, then in propyleneoxide, and finally embedded in Epon 812. After mounting the ultra thin sections on mesh grids (six to eight sections/grid), they were counterstained and observed under a JEM-1230 electron microscope (JEOL Ltd., Tokyo, Japan).

Immunofluorescence

The ice-frozen sections were incubated with CM1 or CM2 hybridoma cell supernatant and anti-CD13 rabbit polyclonal antibody (Santa Cruz Biotech Inc.), then reacted with FITC-conjugated goat anti-mouse secondary antibody and tetraethyl rhodamine isothiocyanate-conjugated goat anti-rabbit secondary antibody (Santa Cruz Biotech Inc.). Sections were washed before visualization with confocal microscope (Fluoview-FV10i, Olympus Corp., Tokyo, Japan).

Purification and isotype assay of antibody

High-titer antibody preparation was obtained from the ascites fluid of mice inoculated intraperitoneally with hybridoma cells (2.5×10^6 cells/mouse). The purification of ascites was performed according to the protocol of antibody purification kit (Pierce, Rockford, IL, USA). Protein concentration was determined using the bovine serum albumin (BSA) protein assay kit (Bio-rad Lab, Hercules, CA, USA). The isotype of monoclonal antibody was identified with Amersham mouse monoclonal antibody isotyping kit (HyCult Biotech, Uden, The Netherlands).

Western blot

The proteins were separated by SDS-PAGE and transferred to the nitrocellulose membrane. Non-specific binding was blocked with TBS buffer (50 mM Tris-HCl and 150 mM NaCl) containing 10% (w/v) skim milk for 2 h at room temperature. Then, the membrane was incubated with hybridoma culture supernatant overnight at 4°C, rinsed with TBS containing 0.05% Tween-20 (TBST) for three times, then followed by incubation with HRP-conjugated goat anti mouse IgG (1:2000 dilution) for 2 h. Finally, the membrane was treated with enhanced chemiluminesence reagent (Santa Cruz Biotech Inc.) and exposed to Kodak X-ray film.

Statistical analysis

All statistical analysis was performed with Student’s t-test by Statistical SPSS software package (Version 12.0; SPSS Inc., Chicago, IL, USA). Differences were considered statistically different at P<0.05.

Results

Distribution of CM1 and CM2 antigens on rat liver tissues

With rat CMVs as immunogens to immunize mice and prepare hybridoma cells, we obtained 46 strains of monoclonal antibodies against CMVs by ELISA screening. Immunohistochemistry assay showed that the distribution of only two strains of mAb, termed as canaliculal mAb1 (CM1) and canaliculal mAb2 (CM2) respectively, were highly distinctive of the hepatocyte canaliculal membrane: anastomosing networks of branched channels as well as circular profiles restricted to regions

Pre-embedding immunogold-silver cytochemistry

Pre-embedding immunogold-silver cytochemistry was performed as previously described.13 The deeply anesthetized rats were perfused transcardially with 150 mL warm saline, followed by 500 mL ice-cold mixture of 4% paraformaldehyde, 0.05% glutaraldehyde, and 15% (v/v) saturated picric acid in 1 M phosphate buffer (pH 7.4) for 2 h. The rat liver tissues were removed and postfixed by immersion in the same fixative for 3 h at 4°C. Serial liver sections of 50 µm thickness were prepared and placed in PBS containing 25% sucrose and 10% glycerol for 1 h. After a freeze-
between adjacent hepatocytes. At high magnification, staining appeared to be associated either with the luminal cell surface or with intraluminal convoluted particles. There was no sinusoidal plasma membrane or intracellular staining of both CM1 and CM2 (Figure 1). In addition, the CM1 antigen was present in the brush border of interlobular bile duct epithelium (Figure 1A), but CM2 antigen was not (Figure 1D). Immunoglobulin subclass determination results showed that the isotypes of both CM1 and CM2 were confirmed to be IgG2a/κ type.

**Distribution of CM1 and CM2 antigens on rat small intestine, colon and kidney tissues**

As intestine and renal tubular epithelial cells also exhibit a striking polarity, we further explored the distribution of CM1 and CM2 antigens on rat small intestine, colon and kidney tissues. It was shown that CM1 and CM2 antigens also specifically expressed on the brush border of small intestine, colon and proximal tubule epithelial cells (Figure 2). However, staining of CM2 antigen on proximal tubule epithelial cells was much less than that of CM1 antigen (Figure 2 C,F). In addition, CM2 antigen was positive at vascular endothelial cells (Figure 2F), but CM1 antigen was negative (data not shown).

**Subcellular localization of CM1 and CM2 antigens in rat hepatocyte**

To confirm the distribution of CM1 and CM2 antigens in rat hepatocyte canalicular membrane, subcellular localization was further determined by immunofluorescence, immuno-electron microscope and organelle protein quantitative analysis. CD13 exhibited a characteristic of strict distribution on the canalicular membrane of hepatocyte, so we observed the co-localization of CD13 and CM1 or CM2 antigens by confocal microscopy. The results showed that CM1 or CM2 antigen stained green was completely overlapping with CD13 stained red in the regions between adjacent hepatocytes (Figure 3 A-C, E-G).

Pre-embedding immunogold-silver cytochemistry also demonstrated that CM1 and CM2 antigens were almost entirely restricted to the canalicular membrane and was negative on the sinusoidal or lateral membrane of hepatocytes (Figure 3 D,H). Furthermore, we quantitatively analyzed the expression of CM1 and CM2 antigens in rat hepatocyte CMVs and SMVs by western blot. It showed that either CM1 or CM2 antigens in rat hepatocyte CMVs was much more than that in hepatocyte SMVs (Figure 4A).

**Identification and characterization of CM1 and CM2 antigens**

Western blot showed CM1 recognized a sin-
ingle protein band with approximately Mr 140kDa and CM2 recognized a broad band at Mr 110kDa with a trailing shoulder (Figure 4A). Furthermore, we evaluated the effect of CM1 or CM2 on glucuronide transport activities of CMVs. It was noted that CM2 but not CM1 could partially inhibit ATP-dependent E217βG uptake of CMVs (Figure 4B). In addition, CM2 inhibited ATP-dependent E217βG uptake of CMVs in a concentration-dependent manner and saturation level was obtained at about 10 μg/mL (Figure 4C).

Figure 3. Subcellular localization of CM1 and CM2 antigens in rat hepatocyte. (A-C and E-G) Co-localization of CD13 and CM1 or CM2 antigens by confocal microscopy. Green fluorescence visualized CM1 and CM2 antigens, red fluorescence visualized CD13 (a marker of hepatocyte canalicular membrane), yellow fluorescence visualized co-localization of CD13 and CM1 or CM2 antigens. D, H) CM1 and CM2 antigens localization on hepatocyte canalicular membrane by Pre-embedding immunogold-silver cytochemistry; CM1 and CM2 antigens were almost entirely restricted to the canalicular membrane of hepatocyte; dots represent CM1 and CM2 antigens.

Figure 4. Identification and characterization of CM1 and CM2 antigens. A) CM1 and CM2 antigens by western blot analysis; molecular mass of CM1 and CM2 antigens were approximately Mr 140 kDa and Mr 110 kDa respectively; either CM1 or CM2 antigens in rat hepatocyte CMVs was much more than that in hepatocyte SMVs. B) Effect on ATP-dependent E217βG uptake activities of CMVs of CM1 or CM2 (10 μg/mL) for different incubated time (0, 5, 10, 15, 20, 25, 30 min); CM2 inhibited most E217βG uptake activities of CMVs at 5 min. C) Effect on ATP-dependent E217βG uptake activities of CMVs of CM2 with different concentration of antibody (1, 2, 5, 10, 20, 50 μg/mL) when incubated for 5 min; CM2 inhibited E217βG uptake of CMVs in a concentration-dependent manner and saturation level was obtained at about 10 μg/mL. Points represented the average ATP-dependent uptake, which subtracted that in the absence of ATP; bars represented the SD. Statistics were performed by Student’s t-test and significance (*) means P<0.05.
**Discussion**

The polarized molecules predominately distributing at hepatocyte canalicular surface play a vital role in disclosing the process of bile formation and etiopathogenesis of cholestatic liver diseases. Therefore, it is important to find novel polarized molecules on hepatocyte canalicular membrane. In our experiments, we utilized hybridoma technique and obtained 46 stains of monoclonal antibodies against rat hepatocyte CMVs, two of which, CM1 and CM2, were confirmed to predominately localize to hepatocyte canalicular membrane. According to their distinct cell-specific distribution, molecular mass and blocking activity of E217βG uptake, it was speculated that CM1 and CM2 antigens could be different polarized molecules on hepatocyte canalicular membrane.

The polarized molecules on hepatocyte canalicular membrane belong to plasma membrane (PM) proteins, which were often difficult to analysis in proteomics studies, due to their low abundant, insoluble, high molecular mass and complicated post-translational modification. Gel-based proteomics strategies, multidimensional liquid chromatography techniques coupled with tandem mass spectrometry (LC-MS/MS), subtractive cDNA strategy and differential display technique were common approaches for studying PM proteomics, but each had different disadvantages. For example, Gel-based proteomics strategies had major limitations of poor sensitivity and narrow dynamic range to hydrophobic PM proteins. LC-MS/MS was a high-throughput screening approach for efficient solubilization of hydrophobic proteins utilizing SDS, but had difficulties for comparative quantitation between biological samples and needing much experiments with morphological and biochemical methods to confirm the results. Subtractive cDNA strategy and differential display technique could analyze the differentially expressed proteins but needed phage-host biology and successful phage display. The hybridoma approach was proved to be a powerful approach to screening PM proteins, which allowed us to use heterogeneous immunogens to obtain the most interesting antigens by further functional screening. For example, rat hepatocyte plasma membrane proteins such as B10 and H4 were found using hybridoma technology and subsequently identified. In our studies, we used subcellular fractions to aggregate the abundance of rat canalicular membrane proteins as heterogeneous immunogens. Meanwhile, we could also use the obtained mAbs to further screen our interesting proteins with morphological and functional methods.

MRP2 was identified to be the only known glucuronide transporter on the hepatocyte canalicular membrane, while many studies illustrated other unknown transporters should also be responsible for the biliary excretion of glucuronide conjugate. Kouzuki et al. found that indomethacin glucuronide transport clearance across the bile canalicular membrane in hepatic Eisai hyperbilirubinemic rats (EHBR) with MRP2 function hereditarily defective was approximately 50% that in Sprague-Dawley rats (SDRs). Nishino et al. confirmed that no significant difference was observed in the biliary excretion of BIBR 277 glucuronide between SDRs and EHBR, although the plasma disappearance of BIBR 277 glucuronide was delayed in EHBR. In our study, we found that CM2 antigen could inhibit ATP-dependent glucuronide uptake of CMVs (Figure 4B) and contribute to the glucuronide excretion.

As previous studies showed, almost all transporters on hepatocyte canalicular membrane such as bile salt-export pump (BSEP), multidrug resistance-1 (MDR1), multidrug resistance-3 (MDR3), MRP2, and breast cancer resistance protein (BCRP) belong to ATP binding cassette (ABC) superfamily proteins. Since the structure of ABC transporters were classified into seven transmembrane proteins, their molecular mass were much more than 140kDa except for BCRP a 72kDa half-transporter protein, which was believed to homodimerize, or possibly oligomerize in order to function. It should be noted that the molecular mass of CM2 antigen was just 110kDa, much less than those of classic ABC transporters. Thus, it could be assumed that

| Species | Proteins | Functions | Expression | Molecular mass (kDa) |
|---------|----------|-----------|------------|---------------------|
| Enzymes | **Enzymes** | **Proteins** | **Functions** | **Expression** | **Molecular mass (kDa)** |
| Rat/human | Alkaline phosphatase (ALP) | Phosphatase | Epithelia and other cells | 63 |
| Rat/human | Dipeptidylpeptidase IV (DPP IV)/CD 26 | Ectopeptidase | Epithelia and other cells | 110 |
| Rat/human | B10 | Alkaline phosphodiesterase | Epithelia | 130 |
| Rat/human | HA4/pp120 cell-CAM 105 | EctoATPase | Epithelia | 105-115 |
| Rat/human | S’ nucleotidase (S’NT) | Nucleotide hydrolase | Liver and other cells | 72 |
| Rat/human | Aminopeptidase N (APN)/CD 13/LAP | Peptidase | Epithelia and fibroblasts | 140-160 |
| Skeleton proteins | **Skeleton proteins** | **Proteins** | **Functions** | **Expression** |
| Rat/human | Ezrin | Membrane/cytoskeleton link | Epithelia and fibroblasts | 81 |
| Channel proteins | **Channel proteins** | **Proteins** | **Expression** |
| Rat/human | Aquaporin 8 (AQP8) | Water channels | Liver and other cells | 30 |
| Exchangers | **Exchangers** | **Proteins** | **Expression** |
| Rat/human | Anion exchanger 2 (AE2) | HCO₃⁻/Cl⁻ anion exchange | Epithelia and other cells | 160 |
| Transporters | **Transporters** | **Proteins** | **Expression** |
| Rat/human | Multidrug resistance-1 (MDR1) / P-glycoprotein (P-gp)/ABCB1 | Pleiotropic membrane transporter | Epithelia and other cells | 170 |
| Human | Multidrug resistance-3 (MDR3)/ABCB3 | Phospholipid transporter | Epithelia and other cells | 170 |
| Rat | Multidrug resistance-2 (Mdr2)/ABCB2 | Phospholipid transporter | Epithelia and other cells | 170 |
| Rat/human | Multidrug resistance-associated protein-2 (MRP2)/ABCC2 | Canalicular conjugate export pump | Epithelia and other cells | 190 |
| Rat/human | Bile salt export pump (BSEP)/Sister of P-glycoprotein (SPGP)/ABCB11 | Canalicular efflux of bile salts | Epithelia and other cells | 160 |
| Rat/human | Breast cancer resistance protein (BCRP) | Canalicular conjugate export pump | Epithelia and other cells | 75 |
| Rat/human | Familial intrahepatic cholestasis-1 (FIC1)/ATP8B1 | Putative aminophospholipid translocator | Liver and other cells | 144 |
CM2 antigen should not belong to ABC transporter and could indirectly participate in glucuronide transport as ABC transporters interacting proteins.

In all the known polarized molecules at hepatocyte canalicular membrane (Table 1), the molecular weight and distribution of CM2 antigen were nearly similar with those of dipeptidylpeptidase IV (DPP-IV) and cell adhesion molecule (cell-CAM) 105. However, DPP-IV, cell-CAM 105 and CM2 antigen actually displayed different characters in some details. First, DPP-IV was positive in the luminal portion of interlobular bile ducts and glomeruli, while CM2 antigen was negative (Figure 1 D,F). Second, CM2 antigen was positive at vascular endothelial cells (Figure 1 F), while CM2 antigen be neither DPP-IV nor cell-CAM 105. Taken together, CM2 antigen predominately distributed at rat hepatocyte canalicular membrane and might be a potential novel molecule participating in glucuronide transport on hepatocyte canalicular membrane.

References

1. Wisher MH, Evans WH. Functional polarity of the rat hepatocyte surface membrane. Isolation and characterization of plasma membrane subfractions from the blood-sinusoidal, bile-canonical and contiguous surfaces of the hepatocyte. Biochim J 1975;146:375-88.

2. Diaz GJ. Basolateral and canalicular transport of xenobiotics in the hepatocyte: A review. Cytotechnology 2000;34:225-35.

3. Roman LM, Hubbard AL. A domain-specific marker for the hepatocyte plasma membrane: localization of leucine aminopeptidase to the bile canalicular domain. J Cell Biol 1983;96: 1548-58.

4. De Broe ME, Roels F, Nouwen EJ, Claeys L, Wieme RJ. Liver plasma membrane: the source of high molecular weight alkaline phosphatase in human serum. Hepatology 1985;5:118-28.

5. Kartenbeck J, Leuschner U, Mayer R, Keppler D. Absence of the canalicular isofom of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 1996;23:1061-6.

6. Paulusma CC, Kool M, Bosman PJ, Scheffer GL, ter Borg F, Scheper RJ, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1997;25:1539-42.

7. Wada M, Toh S, Taniguchi K, Nakamura T, Uchiumi T, Kohno K, et al. Mutations in the canalicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transport gene, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet 1998;7:203-7.

8. Bull LN, van Eijk MJ, Pawlikowska L, DeYoung JA, Julin JA, Liao M, et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 1998;18:219-24.

9. Solis Herruzo JA, Solis Munoz P, Munoz Yague T. The pathogenesis of primary biliary cirrhosis. Rev Esp Enferm Dig 2009;101:413-23.

10. Tietz PS, Holman RT, Miller LJ, LaRussso NF. Isolation and characterization of rat cholangiocyte vesicles enriched in apical or basolateral plasma membrane domains. Biochemistry 1995;34:15436-43.

11. Mazzone A, Tietz P, Jefferson J, Pagano R, LaRussso NF. Isolation and characterization of lipid microdomains from apical and basolateral plasma membranes of rat hepatocytes. Hepatology 2006;43:287-96.

12. Wang JB, Zhou XM, Liu JM, Yan L, Liang J, Zhai HH, et al. Fractionation and collect hepatocyte canalicular membrane vesicles of rats and study their transportation functions in vitro. [in Chinese]. Chin J Hepatol 2007;15: 617-8.

13. Liu JP, Liu YY, Wong-Riley MT, Liu HL, Ju G. A group of neurokinin-1 receptor-immunoactive neurons expressing phospho-extracellular signal-regulated protein kinase in the pre-Botzinger complex of rats. J Neurosci Res 2005;80:260-7.

14. Huang L, Smit JW, Meijer DK, Vore M. Mrp2 is essential for estradiol-17beta(beta-D-glu- curonide)-induced cholestasis in rats. Hepatology 2000;32:66-72.

15. Rocken C, Licht J, Roessner A, Carl-McGrath S. Canaliculal immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma. J Clin Pathol 2005;58:1069-75.

16. Scherer PE, Bickel PE, Kottler M, Lodish HF. Cloning of cell-specific secreted and surface proteins by subtractive antibody screening. Nat Biotechnol 1998;16:581-6.

17. Chambers G, Lawrie I, Cash P, Murray GL. Proteomics: a new approach to the study of disease. J Pathol 2000;192:280-8.

18. Aeberson R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207.

19. Scherer PE, Bickel PE, Kottler M, Lodish HF. Cloning of cell-specific secreted and surface proteins by subtractive antibody screening. Nat Biotechnol 1998;16:581-6.

20. Stern M, Hermann R. Overview of monoclonal antibodies in cancer therapy: past and present. Neoplasia 2005;7:11-29.

21. Steinitz M. Three decades of human monoclonal antibodies: past, present and future developments. Hum Antibodies 2009;18:1-10.

22. Meerson NR, Deautrier D, Durand-Schneider AM, Moreau A, Schilsky ML, Sternlieb I, et al. Identification of B10, an alkaline phosphodiesterase of the apical plasma membrane of hepatocytes and biliary cells, in rat serum: increased levels following bile duct ligation and during the development of cholangiocarcioma. Hepatology 1998;27:563-8.

23. Krause P, Rave-Frank M, Wolf HA, Becker H, Christiansen H, Koenig S. Liver sinusoidal endothelial and biliary cell repopulation following irradiation and partial hepatectomy. World J Gastroenterol 2010;16:3928-35.

24. Kouzuki H, Suzuki H, Sugiyama Y. Pharmacokinetic study of the hepatobiliary transport of indoethanil. Pharm Res 2000; 17:432-8.

25. Nishino A, Kato Y, Igarashi T, Sugiyama Y. Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisartan. Drug Metab Dispos 2000;28: 1146-8.

26. Dean M. ABC Transporters, Drug Resistance, and Cancer Stem Cells. J Mammary Gland Biol Neoplasia 2009;14:3-9.

27. Kos V, Ford R. The ATP-binding cassette family: a structural perspective. Cell Mol Life Sci 2009;66:3111-26.

28. Sauvage Y, Aubert D, Escotte-Binet S, Villena I. The role of ATP-binding cassette (ABC) proteins in protozoan parasites. Mol Biochem Parasitol 2009;167:81-94.

29. Uggla B, Stahl E, Wågsäter D, Paul C, Karlsson MG, Sirsjo A, et al. BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leuk Res 2005;29:141-6.

30. Becker A, Lucka L, Kiliar C, Kannicht C, Reutter W. Characterisation of the ATP-dependent taurocholate-carrier protein (gp110) of the hepatocyte canalicular membrane. Eur J Biochem 1993;214:539-48.

31. Iwaki-Egawa S, Watanabe Y, Fujimoto Y. Identification of a rat liver dipeptidyl aminopeptidase IV with a liver plasma membrane glycoprotein (gp110) A study using dipeptidyl aminopeptidase IV-deficient rats. FEBS Lett 1991;286:167-70.

32. Lucka I, Cichocka I, Bäumler K, Bechler K, Reutter W. A Short Isoform of Carcinoembryonic-Antigen-Related Rat Liver Cell-Cell Adhesion Molecule (C-CAM/gp110) Mediates Intercellular Adhesion. Eur J Biochem 1995;234:527-35.

33. McCaughan GW, Wickson JE, Creswick PF, Gorrell MD. Identification of the bile canalicular cell surface molecule GP110 as the ectopeptidase dipeptidyl peptidase IV: an analysis by tissue distribution, purification and N-terminal amino acid sequence. Hepatology 1990;11:534-44.